Compare EIC & CRBP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | EIC | CRBP |
|---|---|---|
| Founded | N/A | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 228.8M | 190.3M |
| IPO Year | 2018 | 2014 |
| Metric | EIC | CRBP |
|---|---|---|
| Price | $9.45 | $7.22 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 6 |
| Target Price | $12.63 | ★ $45.50 |
| AVG Volume (30 Days) | 92.1K | ★ 941.1K |
| Earning Date | 05-27-2026 | 05-08-2026 |
| Dividend Yield | ★ 13.25% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $4,822,272.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $116.00 |
| P/E Ratio | $9.08 | ★ N/A |
| Revenue Growth | N/A | ★ 97.62 |
| 52 Week Low | $9.17 | $6.33 |
| 52 Week High | $13.55 | $20.56 |
| Indicator | EIC | CRBP |
|---|---|---|
| Relative Strength Index (RSI) | 24.23 | 30.93 |
| Support Level | $9.33 | $6.33 |
| Resistance Level | $10.14 | $8.54 |
| Average True Range (ATR) | 0.13 | 0.74 |
| MACD | -0.04 | -0.15 |
| Stochastic Oscillator | 2.67 | 16.86 |
Eagle Point Income Co Inc is a closed-end management investment company. Its primary investment objective is to generate high current income, with a secondary objective to generate capital appreciation. The Company seeks to achieve its investment objectives by investing in junior debt tranches of collateralized loan obligations, or "CLOs," that are collateralized by a portfolio consisting of below-investment grade U.S. senior secured loans with a large number of distinct underlying borrowers across various industry sectors.
Corbus Pharmaceuticals Holdings Inc is a clinical stage company focused on new therapies in oncology and obesity and is committed to helping people defeat serious illness by bringing inventive scientific approaches to well-understood biological pathways. The company's development pipeline includes; CRB-701, a next-generation antibody-drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGF expressed on cancer cells, and CRB-913 a second-generation peripherally restricted CB1 receptor inverse agonist designed to treat obesity.